
WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I),


or a pharmaceutically acceptable salt thereof, wherein:

Ring B is a 6-membered aromatic ring, which ring is unsubstituted or substituted with 1 to 4 substituents independently selected from halo, -OH, $-NH_2$, $-CH_3$, $-CH_2F$, $-CHF_2$ and $-CF_3$; or is a 5- or 6-membered heteroaromatic ring having 1 to 3 ring heteroatoms independently selected from O, N and S, which ring is unsubstituted or substituted with 1 to 3 substituents independently selected from halo, -OH, $-NH_2$, $-CH_3$, $-CH_2F$, $-CHF_2$ and $-CF_3$;

A^1 is -H or C_{1-3} alkyl; and

A^2 is $-C(R^7)(R^8)-(CH_2)_p-N(R^9)R^{10}$;

or A^1 and A^2, together with the carbon atom to which they are attached, form



;

m is 0, 1 or 2;

n1 is 1 or 2;

n2 is 0 or 1;

n3 is 0 or 1;

p is 0 or 1;

R is -H or C_1-C_3 alkyl; or R is $-CH_2$-(X), $-CH_2CH_2$-(X), $-CH_2$-(Z) or $-CH_2CH_2$-(Z);

each instance of R^5 independently is halo, $-CH_3$ or ethyl;

each instance of R^6 independently is halo or $-CH_3$;


R^7 is -H or C_1-C_3 alkyl;

R^8 is -H or C_1-C_3 alkyl which is unsubstituted or substituted with C_3-C_6 cycloalkyl;

R^9 is -H, C_1-C_4 alkyl or C_3-C_6 cycloalkyl; and


R^{10} is -H or C_1-C_3 alkyl;

or R^9 and R^8, together with the atoms to which they are attached, form



;

or R^9 and R^{10}, together with the nitrogen atom to which they are attached, form



;

w is 0, 1 or 2;

X is CH or CH_2; and


Z is CH, CH_2 or O.

2. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein A^1 is -H.

3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein w is 0.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein n1 is 1 or 2.

5. The compound of claim 1 of Formula (I-1):




(I-1),

or a pharmaceutically acceptable salt thereof, wherein:

R^1, R^2, R^3 and R^4 are independently -H, halo, -OH, $-NH_2$, $-CH_3$, $-CH_2F$, $-CHF_2$ or $-CF_3$.

6. The compound of claim 5 or a pharmaceutically acceptable salt thereof, wherein R^1, R^2, R^3 and R^4 are independently -H, -F or -Cl.

7. The compound of claim 1 of Formula (I-2):



(I-2),

or a pharmaceutically acceptable salt thereof, wherein:

Y^1 is N or $CR^{1'}$;

Y^2 is N or $CR^{2'}$;

Y^3 is N or $CR^{3'}$; and


Y^4 is N or $CR^{4'}$;

wherein 1 to 3 of Y^1, Y^2, Y^3 and Y^4 are N; and

$R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ are independently -H, halo, -OH, $-NH_2$, $-CH_3$, $-CH_2F$, $-CHF_2$ or $-CF_3$.

8. The compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein Y^3 is N.

9. The compound of claim 1 of Formula (I-3):



(I-3),

or a pharmaceutically acceptable salt thereof, wherein:

Y^{11} is $CR^{1''}$ or a heteroatom selected from O, S, N and NR^{11};

Y^{12} is $CR^{2''}$ or a heteroatom selected from O, S, N and NR^{12}; and

Y^{13} is $CR^{3''}$ or a heteroatom selected from O, S, N and NR^{13};


wherein at least one of Y^{11}, Y^{12} and Y^{13} is a heteroatom;

$R^{1''}$, $R^{2''}$ and $R^{3''}$ are independently -H, halo, -OH, $-NH_2$, $-CH_3$, $-CH_2F$, $-CHF_2$ or $-CF_3$; and

R^{11}, R^{12} and R^{13} are independently -H or $-CH_3$.

10. The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein Y^{11} is S.


11. The compound of claim 5, of formula (II-1):



(II-1),

or a pharmaceutically acceptable salt thereof.


12. The compound of claim 11, of formula (II-1a):




(II-1a),

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 11 or a pharmaceutically acceptable salt thereof, wherein R^9 and R^{10}, together with the nitrogen atom to which they are attached, form




14. The compound of claim 5, of formula (III-1):



(III-1),

or a pharmaceutically acceptable salt thereof.


15. The compound of claim 14, of formula (III-1a):



(III-1a),

or a pharmaceutically acceptable salt thereof.













16. The compound of claim 5, of formula (IV-1):























(IV-1),











or a pharmaceutically acceptable salt thereof.











17. The compound of claim 1 selected from a compound shown below, or a pharmaceutically acceptable salt thereof:











 **1**	 **2**
 **3**	 **4**
 **5**	 **6**
 **7**	 **8**
 **9**	 **10**
 **11**	 **12**









 **13**	 **14**
 **15**	 **16**
 **17**	 **18**
 **19**	 **20**
 **21**	 **22**

 **23**	 **24**
 **25**	 **26**
 **27**	 **28**
 **29**	 **30**
 **31**	 **32**


 **33**	 **34**
 **35**	 **36**
 **37**	 **38**
 **39**	 **40**
 **41**	 **42**

 **43**	 **44**
 **45**	 **46**
 **47**	 **48**
 **49**	 **50**
 **51**	 **52**

 **53**	 **54**
 **55**	 **56**
 **57**	 **58**
 **59**	 **60**
 **61**	 **62**


 **63**	 **64**
 **65**	 **66**
 **67**	 **68**
 **69**	 **I-4.**


18. The compound of claim 17, wherein the compound is



or a pharmaceutically acceptable salt thereof.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, selected from:




or


,

or a mixture thereof.

20. The compound of claim 19, wherein the compound is



,

or a pharmaceutically acceptable salt thereof.

21. A composition comprising the compound of any one of claims 1 to 20 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

22. The composition according to claim 21, wherein said composition is a pharmaceutically acceptable composition.

23. Use of the compound according to any one of claims 1 to 20 in the manufacture of a medicament for treating a neurological or psychiatric disorder in a patient.

24. The use according to claim 23, wherein the neurological or psychiatric disorder is depression, pyschosis, suicidality, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism or cognitive impairments.

25. The use according to claim 24, wherein the neurological or psychiatric disorder is depression.

26. The use according to claim 25, wherein the depression is treatment-resistant depression (TRD), major depressive disorder (MDD), unipolar depression, bipolar depression or depression associated with another disease or disorder.

27. A compound according to claim 1 for use in therapy, wherein the compound is to be used as analgesic or a cognitive enhancer.